Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
| Country | France |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | Daniel Tassé |
Contact Details
Address: 177-181 Avenue Pierre Brossolette Montrouge, 92120 France | |
| Phone | 33 1 55 42 78 78 |
| Website | dbv-technologies.com |
Stock Details
| Ticker Symbol | DBVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001613780 |
| CUSIP Number | 23306J101 |
| ISIN Number | US23306J1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel Tassé | Chief Executive Officer |
| Virginie Simone Jeanine Boucinha | Chief Financial Officer |
| Kevin Malobisky | Chief Operating Officer |
| Katie Matthews | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | F-6 POS | Post-effective amendments for immediately effective filing |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Oct 22, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |